Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pyridostigmine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Gains FDA Nod for Pyridostigmine Bromide Extended-Release Tablets
Details : Pyridostigmine Bromide, is a cholinesterase inhibitor small molecule drug administered orally for soman nerve agent poisoning in adults.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Pyridostigmine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Milla Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A.forall Announces Launch of a Generic Version of Pyridostigmine Bromide Syrup
Details : Pyridostigmine Bromide, generic version of Mestinon, is a cholinesterase inhibitor small molecule drug administered orally as a syrup for myasthenia gravis.
Product Name : Mestinon-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Milla Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : NMD PHARMA
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyridostigmine and Amifampridine for Myasthenia Gravis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2023
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : NMD PHARMA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Alter Pharma group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.
Product Name : Pyridostigmine Bromide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Alter Pharma group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Novo Nordisk | Svend Faelding Humanitarian Foundation | Copenhagen University Foundation for Medical Students | Hoejmosegaard Foundation | Holger Rabitz og Hustru Doris Mary foedt Phillipps Mindelegat | Lundbeck Foundation | Wilhelm Frank og Angelina Fran
Deal Size : Inapplicable
Deal Type : Inapplicable
Gastrointestinal Motility Among Diabetes Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2015
Lead Product(s) : Pyridostigmine
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Novo Nordisk | Svend Faelding Humanitarian Foundation | Copenhagen University Foundation for Medical Students | Hoejmosegaard Foundation | Holger Rabitz og Hustru Doris Mary foedt Phillipps Mindelegat | Lundbeck Foundation | Wilhelm Frank og Angelina Fran
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of Pyridostigmine in Heart Failure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2011
Lead Product(s) : Pyridostigmine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Nathan Kline Institute for Psychiatric Research | Oklahoma State University | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable